Congenital Cytomegalovirus Infection Clinical Trial
Official title:
Congenital Cytomegalovirus Infection by Detection of the Virus in the Saliva of Newborns at Particular Risk: A Retrospective Population-based Study Between February 2019 and December 2021 at the Regional Maternity Hospital of Nancy
Congenital CMV infection is the leading cause of non-genetic deafness and neurodevelopmental disorders. Its prevalence in France is estimated between 0.3% and 1% of births depending on the study. Congenital infection is symptomatic in 10% of cases with a large clinical spectrum with different degree of severity. These sequelae develop progressively and fluctuate, which justifies prolonged follow-up of children for several years, even if they are asymptomatic at birth. There is yet no treatment with AMM in neonates or pregnant women. In France, screening for congenital CMV infection is widely debated. It remains oriented to certain newborns considered at risk or depending on their symptoms and varies with the practices of each Neonatology or Maternity Hospital. In the Regional Maternity of Nancy, a new screening protocol for congenital CMV infection was implemented from early 2019. It is based on screening by non-invasive salivary test (CMV PCR) in newborns at particular risk who are included in a registry open for this screening. The aim of this research was to assess the relevance of the proposed criteria in the Protocol for defining a population at risk of congenital CMV infection thus qualifying for CMV screening. The secondary endpoints are the modalities of the screening test, the evaluation of each risk factor for infection, and the study of affected patients (symptoms, therapeutic intervention, neurological and auditory outcome).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01923636 -
Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero
|
N/A | |
| Recruiting |
NCT03973359 -
Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy
|
N/A | |
| Completed |
NCT02005822 -
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
|
Phase 3 | |
| Completed |
NCT02139423 -
Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening
|
N/A | |
| Withdrawn |
NCT02594566 -
Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
|
Phase 1 | |
| Completed |
NCT02351102 -
Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05170269 -
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
|
Phase 3 | |
| Not yet recruiting |
NCT06118515 -
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
|
Phase 1 | |
| Completed |
NCT02782988 -
Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
|
||
| Completed |
NCT02645396 -
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
|
||
| Terminated |
NCT01655212 -
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
|
Phase 3 | |
| Completed |
NCT02710864 -
A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
|
||
| Terminated |
NCT03301415 -
Asymptomatic Congenital CMV Treatment
|
Phase 2 | |
| Completed |
NCT01376778 -
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
|
Phase 3 |